Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04672252 · ClinicalTrials.gov registry record · Phase 2
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT04672252 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 100 participants.
The verdict
NCT04672252, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effects of administering CBD to control post-operative pain in patients undergoing shoulder arthroscopy. Secondly, the purpose will be to evaluate the effectiveness of CBD in comparison with opioid therapy for post-operative pain.
Interventions
- DRUG CBD Oral Disintegrating Tablet (ODT)
- OTHER Placebo ODT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04672252
The ClinicalTrials.gov registry entry for NCT04672252 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CBD Oral Disintegrating Tablet (ODT) is the first listed.
NCT04672252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04672252 about?
NCT04672252 is a clinical study titled "The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy". This study is designed to evaluate the effects of administering CBD to control post-operative pain in patients undergoing shoulder arthroscopy. Secondly, the purpose will be to evaluate the effectiveness of CBD in comparison with opioid therapy for post-operative pain.
What is the current status of trial NCT04672252?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-12-01. Estimated completion is 2022-12-16.
What interventions are being tested in trial NCT04672252?
The interventions under investigation include: CBD Oral Disintegrating Tablet (ODT) (DRUG), Placebo ODT (OTHER).
Who is sponsoring clinical trial NCT04672252?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.